Data updated: Jun 28, 2026
RSV Clinical Trial Landscape
RSV is being studied across 285 clinical trials registered since 2008, with 57 programs currently active. The competitive pipeline includes 16 active Phase 3 trials, 20 active Phase 2 trials, and 15 active Phase 1 trials.
Trial activity
57 active / 285 total since 2008
Active by phase 16 Ph3 / 70 20 Ph2 / 100 15 Ph1 / 107 6 Ph4 / 8
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
GSK 6 30 4
Pfizer 3 15 4
Shenzhen Shenxin Biotechnology Co., Ltd 3 0 0
MAXVAX Biotechnology Limited Liability Company 3 0 0
Guangzhou Patronus Biotech Co., Ltd. 3 0 0
Sanofi 2 10 2
ModernaTX, Inc. 2 9 0
Suzhou Abogen Biosciences Co., Ltd. 2 0 0
Enanta Pharmaceuticals, Inc 1 15 1
Shanghai Ark Biopharmaceutical Co., Ltd. 1 4 2
Clover Biopharmaceuticals AUS Pty 1 1 1
Blue Lake Biotechnology Inc. 1 1 0
Codagenix, Inc 1 1 0
Shionogi 1 0 0
Immorna Biotherapeutics, Inc. 1 0 0
How the field has grown
New-trial starts peaked in 2024 (34 registered); 2025 saw 28. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (62 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 16
2017 12
2018 15
2019 14
2020 15
2021 24
2022 26
2023 26
2024 34
2025 28
2026 13
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (2) 125
2017 (0) 0
2018 (0) 0
2019 (2) 1,969
2020 (2) 5,753
2021 (13) 1,028
2022 (9) 1,471
2023 (10) 999
2024 (13) 751
2025 (7) 550
2026 (4) 394
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT06866405 RECRUITING
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
Pfizer n=550
NCT06593210 ACTIVE NOT RECRUITING
RSV Vaccine in Transplant Recipients
University Health Network, Toronto n=100
NCT07543380 RECRUITING
A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
Pfizer n=130
NCT06534892 ACTIVE NOT RECRUITING
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
GlaxoSmithKline n=10,212
NCT07220109 RECRUITING
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
GlaxoSmithKline n=750
NCT07402512 RECRUITING
A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children
Simcere Pharmaceutical Co., Ltd n=498
NCT04732871 ACTIVE NOT RECRUITING
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
GlaxoSmithKline n=1,720
NCT05026749 RECRUITING
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
University of Alabama at Birmingham n=370
NCT07272434 RECRUITING
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
MAXVAX Biotechnology Limited Liability Company n=25,000
NCT06067230 ACTIVE NOT RECRUITING
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ModernaTX, Inc. n=1,153
NCT06955728 RECRUITING
A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.
University of Witwatersrand, South Africa n=13,000
NCT06267118 RECRUITING
Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis
Combined Military Hospital, Pakistan n=60
NCT06363370 RECRUITING
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections
Kexing Biopharm Co., Ltd. n=322
NCT07658534 RECRUITING
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.
Shanghai Ark Biopharmaceutical Co., Ltd. n=290
NCT07653100 NOT YET RECRUITING
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
Pfizer n=540
NCT04938830 COMPLETED
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
Merck Sharp & Dohme LLC n=1,003
NCT07117487 COMPLETED
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
ModernaTX, Inc. n=507
NCT06042049 COMPLETED
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
AstraZeneca n=33
NCT05705440 COMPLETED
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
GlaxoSmithKline n=3,855
NCT06083623 COMPLETED
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
Zhuhai Trinomab Pharmaceutical Co., Ltd. n=2,282
NCT06710925 COMPLETED
A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants
Zhuhai Trinomab Pharmaceutical Co., Ltd. n=315
NCT04767373 COMPLETED
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
Merck Sharp & Dohme LLC n=3,632
NCT06551181 COMPLETED
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
GlaxoSmithKline n=2,620
NCT06593587 COMPLETED
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea
Pfizer n=378
NCT06252285 TERMINATED
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur, a Sanofi Company n=6,300
NCT06705140 TERMINATED
A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur, a Sanofi Company n=947
NCT05330975 COMPLETED
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
ModernaTX, Inc. n=3,317
NCT06374394 COMPLETED
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
GlaxoSmithKline n=841
NCT06614725 COMPLETED
A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)
GlaxoSmithKline n=751
NCT06079320 TERMINATED
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
Pfizer n=16
NCT06890416 COMPLETED
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
Pfizer n=526
NCT06473519 COMPLETED
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
Pfizer n=453
NCT06389487 COMPLETED
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
GlaxoSmithKline n=1,459
NCT05127434 COMPLETED
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. n=36,814
NCT05842967 COMPLETED
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
Pfizer n=885
NCT04886596 COMPLETED
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
GlaxoSmithKline n=26,675
NCT06060457 COMPLETED
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
ModernaTX, Inc. n=1,900
NCT06325657 COMPLETED
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
Pfizer n=648
NCT05083585 COMPLETED
A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old
Janssen Vaccines & Prevention B.V. n=250
NCT05070546 COMPLETED
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
Janssen Vaccines & Prevention B.V. n=1,124
NCT05101486 COMPLETED
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
Janssen Vaccines & Prevention B.V. n=755
NCT05242432 TERMINATED
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
Janssen Pharmaceutical K.K. n=2,192
NCT05879107 COMPLETED
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
GlaxoSmithKline n=1,113
NCT02624947 COMPLETED
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
Novavax n=4,636
NCT04980391 TERMINATED
A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
GlaxoSmithKline n=384
NCT05966090 COMPLETED
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
GlaxoSmithKline n=530
NCT05590403 COMPLETED
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
GlaxoSmithKline n=1,544
NCT04605159 TERMINATED
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
GlaxoSmithKline n=11,194
NCT05559476 COMPLETED
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
GlaxoSmithKline n=1,029
NCT05568797 COMPLETED
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
GlaxoSmithKline n=1,045
NCT04841577 COMPLETED
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
GlaxoSmithKline n=976
NCT03979313 COMPLETED
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)
AstraZeneca n=3,012
NCT04231968 COMPLETED
A Study of AK0529 in Chinese Infants Hospitalized With RSV
Shanghai Ark Biopharmaceutical Co., Ltd. n=311
NCT05301322 COMPLETED
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
Pfizer n=1,471
NCT05045144 COMPLETED
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
GlaxoSmithKline n=1,586
NCT03959488 COMPLETED
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
AstraZeneca n=925
NCT05096208 COMPLETED
Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age
Pfizer n=1,028
NCT05169905 COMPLETED
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
GlaxoSmithKline n=9
NCT05059301 COMPLETED
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
GlaxoSmithKline n=770
NCT02608502 COMPLETED
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
Novavax n=11,850
NCT02911935 COMPLETED
Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II
Washington University School of Medicine n=200
NCT05229068 WITHDRAWN
A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
GlaxoSmithKline
NCT02325791 COMPLETED
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Regeneron Pharmaceuticals n=1,177
NCT02968173 COMPLETED
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
AbbVie n=50
NCT01466062 COMPLETED
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
AbbVie (prior sponsor, Abbott) n=28
NCT01006629 COMPLETED
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
Abbott n=100
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only